...
首页> 外文期刊>The lancet oncology >Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study.
【24h】

Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study.

机译:幽门螺杆菌作为胃癌根治性切除后的预后指标:一项前瞻性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The effect of Helicobacter-pylori status on survival after curative resection for gastric adenocarcinoma is unknown. We aimed to follow-up patients who were positive or negative for infection with H pylori who had curative (ie, R0) resection for gastric adenocarcinoma to assess differences in relapse-free survival and overall survival. METHODS: Before surgery, we assessed the H pylori status of 166 patients who had R0 resection for gastric adenocarcinoma between 1992 and 2002 with bacterial culture, histological analyses (ie, staining with haematoxylin and eosin and with Warthin-Starry), and serological analyses. FINDINGS: At a median follow-up of 53.0 months (range 1-146), relapse-free survival was 56.7 months (95% CI 4.7-108.7) and overall survival was 61.9 months (13.0-110.9) in patients positive for H pylori, compared with 19.2 months (12.7-25.6) and 19.2 months (7.1-31.3), respectively, in patients negative for H pylori (p=0.0009 for difference in relapse-free survival between groups, and p=0.0017 for difference in overall survival between groups). In multivariate analyses, H pylori was an independent prognostic factor for relapse-free survival (hazard ratio 2.16 [95% CI 1.33-3.49]) and overall survival (2.00 [1.22-3.27]). Depth of tumour invasion (2.60 [1.66-4.08]), lymph-node metastasis (2.11 [1.25-3.57]), and patient age 67.5 years or older (1.75 [1.11-2.75]) were also independent prognostic factors for overall survival. INTERPRETATION: Tumour-specific immune responses might be downregulated in patients who are negative for H pylori, and these patients should be followed up carefully because of a poor outlook.
机译:背景:幽门螺杆菌状态对胃腺癌根治性切除术后生存的影响尚不清楚。我们的目的是随访对胃腺癌进行治愈性(即R0)切除的幽门螺杆菌感染阳性或阴性的患者,以评估无复发生存率和总生存率的差异。方法:在手术前,我们通过细菌培养,组织学分析(即用苏木精和曙红染色,并用Warthin-Starry染色)和血清学分析评估了166例1992年至2002年间行R0切除的胃腺癌患者的幽门螺杆菌状态。结果:幽门螺杆菌阳性患者中位随访时间为53.0个月(范围1-146),无复发生存期为56.7个月(95%CI 4.7-108.7),总生存期为61.9个月(13.0-110.9)。幽门螺杆菌阴性的患者分别为19.2个月(12.7-25.6)和19.2个月(7.1-31.3)(两组之间无复发生存率差异为p = 0.0009,总体生存率差异为p = 0.0017组之间)。在多因素分析中,幽门螺杆菌是无复发生存(危险比2.16 [95%CI 1.33-3.49])和总生存(2.00 [1.22-3.27])的独立预后因素。肿瘤浸润深度(2.60 [1.66-4.08]),淋巴结转移(2.11 [1.25-3.57])和患者年龄67.5岁或以上(1.75 [1.11-2.75])也是整体生存的独立预后因素。解释:幽门螺杆菌阴性的患者的肿瘤特异性免疫反应可能被下调,由于前景不佳,应仔细随访这些患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号